The efficacy of immune checkpoint inhibitors in thoracic malignancies Source: Eur Respir Rev, 30 (162) 200387; 10.1183/16000617.0387-2020 Year: 2021
Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis Source: Eur Respir J, 55 (6) 2000038; 10.1183/13993003.00038-2020 Year: 2020
Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study Source: ERJ Open Res, 6 (1) 00165-2019; 10.1183/23120541.00165-2019 Year: 2020
Immune checkpoint inhibitors in lung cancer Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine Year: 2016
Predictive biomarker of immune checkpoint inhibitors efficacy Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
Immune checkpoint inhibitor-associated interstitial lung diseases: some progress but still many issues Source: Eur Respir J, 50 (2) 1701319; 10.1183/13993003.01319-2017 Year: 2017
Emerging concern of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer Source: Eur Respir Rev, 28 (153) 190058; 10.1183/16000617.0058-2019 Year: 2019
Signs of MICA as an innate immune molecule potentially involved in vascular remodelling in patients with pulmonary hypertension Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010
The clinical benefits of immune checkpoint inhibitors for thymic carcinomas Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018
Micro-RNA-125a/b target A20 and MAVS to promote inflammatory and impair antiviral responses in chronic obstructive pulmonary disease Source: International Congress 2016 – Mechanisms of disease Year: 2016
Targeting the mTOR signaling pathway to inhibit lung cell senescence in chronic obstructive pulmonary disease (COPD) Source: ERS Lung Science Conference 2017 Year: 2017
Immune checkpoint and COPD Source: ERS Lung Science Conference 2017 Year: 2017
The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020
Mitochondrial antiviral signaling protein is crucial for the development of pulmonary fibrosis Source: Eur Respir J, 57 (4) 2000652; 10.1183/13993003.00652-2020 Year: 2021
Pulmonary and systemic cellular immune response network in patients with mild-moderate COPD Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017
Evaluation of serial interferon-gamma release assay testing in lung cancer patients treated with immune checkpoint inhibitors Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis Year: 2021
Immune checkpoints in chronic obstructive pulmonary disease Source: Eur Respir Rev, 26 (144) 170045; 10.1183/16000617.0045-2017 Year: 2017
Role of cytokines in regulation of inflammatory and protective reactions in progression of pulmonary MDR tuberculosis Source: Annual Congress 2007 - New methods to diagnose tuberculosis infection and disease and problems in tuberculosis care Year: 2007